Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WALGREENS BOOTS ALLIANCE, INC.

(WBA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WALGREENS BOOTS ALLIANCE, INC. : Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

06/04/2021 | 05:12pm EDT

Item 2.01. Completion of Acquisition or Disposition of Assets.

On June 1, 2021, Walgreens Boots Alliance, Inc. (the "Company") completed the previously announced sale pursuant to the Share Purchase Agreement, dated January 6, 2021 (the "Share Purchase Agreement"), with AmerisourceBergen Corporation ("AmerisourceBergen"). Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen purchased (the "Transaction") the majority of the Company's Alliance Healthcare business (the "Business") for approximately $6.5 billion, comprised of $6.275 billion in cash, subject to certain purchase price adjustments, and 2,000,000 shares of AmerisourceBergen common stock. After giving effect to the Transaction, the Company beneficially owns approximately 28.4% of AmerisourceBergen's outstanding common stock, $0.01 par value per share (based on the number of shares of common stock outstanding as of April 30, 2021, as represented by AmerisourceBergen in the most recent Form 10-Q filed by AmerisourceBergen on May 5, 2021) plus the 2,000,000 shares of common stock transferred to the Company's subsidiary upon consummation of the Transaction. As a result of such ownership, pursuant to the A&R Shareholders Agreement (as defined below), the Company is entitled to appoint one member of the board of directors of AmerisourceBergen.

In connection with the closing of the Transaction, the previously announced three-year extension through 2029 of the U.S. pharmaceutical distribution agreement between the Company and AmerisourceBergen became effective. Pursuant to the U.S. pharmaceutical distribution agreement, the Company's branded and generic pharmaceutical products are sourced from AmerisourceBergen in the U.S.

The foregoing description of the Share Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the full text of the Share Purchase Agreement, which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on January 8, 2021 and is incorporated herein by reference. The representations, warranties and covenants in the Share Purchase Agreement were made solely for the benefit of the parties to the Share Purchase Agreement for the purpose of allocating contractual risk between those parties, and do not establish these matters as facts. Investors should not rely on the representations, warranties and covenants as characterizations of the actual state of facts or condition of the Company, AmerisourceBergen or any of their respective subsidiaries or affiliates.

Item 1.01. Entry into a Material Definitive Agreement.

In connection with the closing of the Transaction, the Company and AmerisourceBergen also entered into an Amended and Restated Shareholders Agreement (the "A&R Shareholders Agreement"), which amends and restates in its entirety the existing Shareholders Agreement of AmerisourceBergen, dated March 18, 2013 (the "Existing Shareholders Agreement"). The A&R Shareholders Agreement, among other things, increases by 1% the percentage of outstanding AmerisourceBergen common stock which the Company and its affiliates are permitted to hold.

The foregoing description of the changes between the Existing Shareholders Agreement and the A&R Shareholders Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R Shareholders Agreement, which is filed as Exhibit 10.1 hereto.

Item 7.01. Regulation FD Disclosure

On June 2, 2021, the Company issued a press release announcing the completion of the Transaction, a copy of which is furnished as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(b) Pro Forma Financial Information

The following unaudited pro forma consolidated condensed financial statements of the Company and accompanying notes giving effect to the Transaction are filed herewith as Exhibit 99.2 and are incorporated herein by reference:



    -    Unaudited pro forma consolidated condensed statements of earnings for the
         fiscal years ended August 31, 2020, August 31, 2019 and August 31, 2018.

No pro forma consolidated condensed statement of earnings for the period ended February 28, 2021 or related balance sheet as of February 28, 2021 are provided in this report, as the Business was presented as discontinued operations in the interim financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended February 28, 2021, filed on March 31, 2021.


(d)  Exhibits



Exhibit                                  Description

10.1          Amended and Restated AmerisourceBergen Shareholders Agreement, dated
            as of June 1, 2021, between AmerisourceBergen Corporation and
            Walgreens Boots Alliance, Inc.

99.1          Press Release issued by Walgreens Boots Alliance, Inc. on June 2,
            2021

99.2          Unaudited Pro Forma Consolidated Condensed Financial Statements

104         Cover Page Interactive Data File (formatted as inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about WALGREENS BOOTS ALLIANCE, INC.
07:11aWALGREENS BOOTS ALLIANCE : VillageMD to Open Village Medical Practices in Indian..
MT
06:16aWALGREENS BOOTS ALLIANCE : and VillageMD Expand to Northern Indiana, Opening New..
BU
07/21Drugmakers, pharmacies next targets for U.S. opioid settlements
RE
07/20New York, drug distributors reach $1.18 billion opioid settlement as national..
RE
07/20WALGREENS BOOTS ALLIANCE, INC. : Change in Directors or Principal Officers (form..
AQ
07/20Walgreens Boots Alliance, Inc. Announces Executive Changes
CI
07/20PLx Shares Rise as Walgreens Set to Carry Vazalore in Stores
DJ
07/19PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwid..
CI
07/16WALGREENS BOOTS ALLIANCE : Target removes J&J sunscreens from stores, website
RE
07/15Pharmacies pull J&J sunscreens off shelves after carcinogen found in some spr..
RE
More news